Target intelligence / Profile preview

Calcium and inorganic phosphate (Ca-Pi)

Target
Ca-Pi
Molecular classification
Inorganic ion, Mineral
01

Overview

Calcium ions (Ca2+) and inorganic phosphate (Pi) are essential minerals that serve as the primary building blocks of the hydroxyapatite matrix in bone and teeth (NIH, 2023). Beyond structural roles, calcium is a ubiquitous second messenger involved in muscle contraction and neurotransmission, while phosphate is vital for cellular energy transfer via ATP and the formation of nucleic acids (StatPearls, 2023). In clinical medicine, these ions are targeted primarily in the management of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD), where impaired renal excretion leads to hyperphosphatemia and reciprocal changes in calcium levels (Kidney International, 2017). Pharmacological management includes phosphate binders like sevelamer or lanthanum carbonate, which sequester inorganic phosphate in the gut to prevent systemic absorption (PubChem). Additionally, calcium-based salts are used both as supplements and as binders to maintain mineral homeostasis and suppress secondary hyperparathyroidism (Mayo Clinic, 2024).

Other names
Calcium phosphateHydroxyapatite componentsMineral bone componentsSerum phosphorus and calcium
02

Mechanism of action

Phosphate binders act by ion exchange or precipitation reactions within the gastrointestinal tract to form insoluble complexes with dietary phosphate, thereby reducing systemic absorption (PubChem). Calcium-based agents increase the available pool of calcium for bone deposition and activate calcium-sensing receptors (CaSR) to modulate endocrine signaling and suppress parathyroid hormone secretion (StatPearls).

03

Biological functions

Bone mineralizationCell signalingEnergy metabolismElectrolyte balanceMuscle contractionBlood coagulation
04

Disease associations

Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)HyperphosphatemiaOsteoporosisVascular calcificationHypocalcemiaSecondary hyperparathyroidism
05

Safety considerations

HypercalcemiaVascular and soft tissue calcificationGastrointestinal constipation or obstructionAdynamic bone diseaseDrug-drug interactions due to chelation in the gut
06

Interacting drugs

Sevelamer

7 more in the full profile.

07

Biomarkers

Serum phosphorus levelsCorrected serum calciumCalcium-phosphate product (Ca x P)Intact parathyroid hormone (iPTH)Fibroblast growth factor 23 (FGF23)

Beyond the preview

Go deeper on Calcium and inorganic phosphate (Ca-Pi).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Calcium and inorganic phosphate (Ca-Pi).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call